Jupiter Topco LLC Makes New $10.22 Million Investment in Aurinia Pharmaceuticals Inc $AUPH

Posted by Stanley Muller on Aug 30th, 2026

Jupiter Topco LLC bought a new position in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Free Report) (TSE:AUP) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 602,195 shares of the biotechnology company’s stock, valued at approximately $10,219,000. Jupiter Topco LLC owned 0.45% of Aurinia Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the stock. MML Investors Services LLC lifted its position in Aurinia Pharmaceuticals by 12.7% during the 4th quarter. MML Investors Services LLC now owns 15,643 shares of the biotechnology company’s stock worth $250,000 after acquiring an additional 1,765 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Aurinia Pharmaceuticals by 15.5% during the first quarter. First Trust Advisors LP now owns 14,065 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 1,883 shares during the period. BOK Financial Private Wealth Inc. acquired a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth $32,000. Concurrent Investment Advisors LLC boosted its stake in shares of Aurinia Pharmaceuticals by 7.8% in the fourth quarter. Concurrent Investment Advisors LLC now owns 30,270 shares of the biotechnology company’s stock valued at $483,000 after purchasing an additional 2,200 shares during the period. Finally, CWM LLC boosted its stake in shares of Aurinia Pharmaceuticals by 15.5% in the fourth quarter. CWM LLC now owns 16,543 shares of the biotechnology company’s stock valued at $264,000 after purchasing an additional 2,225 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Insider Activity

In other news, CEO Kevin Tang purchased 343,620 shares of Aurinia Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was bought at an average price of $15.28 per share, with a total value of $5,250,513.60. Following the completion of the acquisition, the chief executive officer owned 12,838,101 shares in the company, valued at $196,166,183.28. The trade was a 2.75% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 10.40% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock opened at $16.29 on Friday. The company has a market cap of $2.17 billion, a P/E ratio of 7.11 and a beta of 1.42. The business has a 50 day moving average of $15.98 and a two-hundred day moving average of $15.49. Aurinia Pharmaceuticals Inc has a 52 week low of $10.34 and a 52 week high of $19.25. The company has a quick ratio of 4.97, a current ratio of 5.42 and a debt-to-equity ratio of 0.07.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last announced its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.04. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%.The business had revenue of $58.57 million for the quarter, compared to the consensus estimate of $80.45 million. As a group, analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.79 EPS for the current year.

Analyst Ratings Changes

AUPH has been the topic of several analyst reports. Weiss Ratings raised shares of Aurinia Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Bloom Burton upgraded Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 21st. Royal Bank Of Canada boosted their price target on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research note on Friday, August 7th. Finally, Wall Street Zen downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $17.67.

Check Out Our Latest Research Report on Aurinia Pharmaceuticals

About Aurinia Pharmaceuticals

(Free Report)

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.